Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

The mouse dystrophin muscle promoter/enhancer drives expression of mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice.

Anderson CL, De Repentigny Y, Cifelli C, Marshall P, Renaud JM, Worton RG, Kothary R.

Mol Ther. 2006 Nov;14(5):724-34. Epub 2006 Jun 27.

2.

The mouse dystrophin muscle enhancer-1 imparts skeletal muscle, but not cardiac muscle, expression onto the dystrophin Purkinje promoter in transgenic mice.

De Repentigny Y, Marshall P, Worton RG, Kothary R.

Hum Mol Genet. 2004 Nov 15;13(22):2853-62. Epub 2004 Sep 22.

PMID:
15385445
3.

Mouse dystrophin enhancer preferentially targets lacZ expression in skeletal and cardiac muscle.

Marshall P, Chartrand N, De Repentigny Y, Kothary R, Pelletier L, Mueller R, Worton RG.

Dev Dyn. 2002 May;224(1):30-8.

4.

The mouse dystrophin enhancer is regulated by MyoD, E-box-binding factors, and by the serum response factor.

Marshall P, Chartrand N, Worton RG.

J Biol Chem. 2001 Jun 8;276(23):20719-26. Epub 2001 Mar 19.

5.

On discovery, genomes, the Society, and society.

Worton RG.

Am J Hum Genet. 2001 Apr;68(4):819-25. Epub 2001 Mar 16. No abstract available.

6.

Transfection of cultured myoblasts in high serum concentration with DODAC:DOPE liposomes.

Vitiello L, Bockhold K, Joshi PB, Worton RG.

Gene Ther. 1998 Oct;5(10):1306-13.

7.

Dystrophin isoforms DP71 and DP427 have distinct roles in myogenic cells.

Howard PL, Dally GY, Ditta SD, Austin RC, Worton RG, Klamut HJ, Ray PN.

Muscle Nerve. 1999 Jan;22(1):16-27.

PMID:
9883853
8.
9.

Identification of a transcriptional enhancer within muscle intron 1 of the human dystrophin gene.

Klamut HJ, Bosnoyan-Collins LO, Worton RG, Ray PN, Davis HL.

Hum Mol Genet. 1996 Oct;5(10):1599-606.

PMID:
8894694
10.

Expression of the dystrophin isoform Dp71 in differentiating human fetal myogenic cultures.

Tennyson CN, Dally GY, Ray PN, Worton RG.

Hum Mol Genet. 1996 Oct;5(10):1559-66.

PMID:
8894689
11.

Stability of the human dystrophin transcript in muscle.

Tennyson CN, Shi Q, Worton RG.

Nucleic Acids Res. 1996 Aug 1;24(15):3059-64.

12.

Condensation of plasmid DNA with polylysine improves liposome-mediated gene transfer into established and primary muscle cells.

Vitiello L, Chonn A, Wasserman JD, Duff C, Worton RG.

Gene Ther. 1996 May;3(5):396-404.

PMID:
9156800
13.

The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced.

Tennyson CN, Klamut HJ, Worton RG.

Nat Genet. 1995 Feb;9(2):184-90.

PMID:
7719347
14.

Dystrophin: the long and short of it.

Worton RG.

J Clin Invest. 1994 Jan;93(1):4. No abstract available.

15.

Genomic organization of exons 22 to 25 of the dystrophin gene.

Bebchuk KG, Bulman DE, D'Souza VN, Worton RG, Ray PN.

Hum Mol Genet. 1993 May;2(5):593-4. No abstract available.

PMID:
8518799
16.

The era of genetic medicine.

Worton RG.

CMAJ. 1993 May 1;148(9):1455. No abstract available.

17.

Myoblast transfer in DMD: problems in the interpretation of efficiency.

Karpati G, Holland P, Worton RG.

Muscle Nerve. 1992 Oct;15(10):1209-10. No abstract available.

PMID:
1406777
18.

Dystrophin in frameshift deletion patients with Becker muscular dystrophy.

Gangopadhyay SB, Sherratt TG, Heckmatt JZ, Dubowitz V, Miller G, Shokeir M, Ray PN, Strong PN, Worton RG.

Am J Hum Genet. 1992 Sep;51(3):562-70.

19.

Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia.

Gillard EF, Otsu K, Fujii J, Duff C, de Leon S, Khanna VK, Britt BA, Worton RG, MacLennan DH.

Genomics. 1992 Aug;13(4):1247-54.

PMID:
1354642
20.

Duchenne muscular dystrophy: gene and gene product; mechanism of mutation in the gene.

Worton RG.

J Inherit Metab Dis. 1992;15(4):539-50. Review.

PMID:
1528015
21.

The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia.

MacLennan DH, Otsu K, Fujii J, Zorzato F, Phillips MS, O'Brien PJ, Archibald AL, Britt BA, Gillard EF, Worton RG.

Symp Soc Exp Biol. 1992;46:189-201. Review.

PMID:
1341035
22.

Frameshift duplication resulting in truncated dystrophin in a patient with Duchenne muscular dystrophy.

Hu X, Bulman DE, Ray PN, Worton RG.

Hum Mutat. 1992;1(2):172-3. No abstract available.

PMID:
1301205
23.

Partial gene duplication as a cause of human disease.

Hu X, Worton RG.

Hum Mutat. 1992;1(1):3-12. Review.

PMID:
1301188
24.

Molecular analysis of X-autosome translocations in females with Duchenne muscular dystrophy.

Bodrug SE, Holden JJ, Ray PN, Worton RG.

EMBO J. 1991 Dec;10(12):3931-9.

25.

A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia.

Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH.

Genomics. 1991 Nov;11(3):751-5.

PMID:
1774074
26.

Physical mapping at a potential X-linked retinitis pigmentosa locus (RP3) by pulsed-field gel electrophoresis.

Musarella MA, Anson-Cartwright CL, McDowell C, Burghes AH, Coulson SE, Worton RG, Rommens JM.

Genomics. 1991 Oct;11(2):263-72.

PMID:
1769646
27.

ASHG human genome committee report. The human genome project: implications for human genetics.

Caskey CT, Worton RG.

Am J Hum Genet. 1991 Sep;49(3):687-91. No abstract available.

29.

A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia.

MacKenzie AE, Allen G, Lahey D, Crossan ML, Nolan K, Mettler G, Worton RG, MacLennan DH, Korneluk R.

Anesthesiology. 1991 Jul;75(1):4-8.

PMID:
2064058
30.

Point mutation in the human dystrophin gene: identification through western blot analysis.

Bulman DE, Gangopadhyay SB, Bebchuck KG, Worton RG, Ray PN.

Genomics. 1991 Jun;10(2):457-60.

PMID:
2071150
31.

Linkage analysis in X-linked ocular albinism.

Schnur RE, Nussbaum RL, Anson-Cartwright L, McDowell C, Worton RG, Musarella MA.

Genomics. 1991 Apr;9(4):605-13.

PMID:
1674724
32.

Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin.

Bulman DE, Murphy EG, Zubrzycka-Gaarn EE, Worton RG, Ray PN.

Am J Hum Genet. 1991 Feb;48(2):295-304.

33.

Dystrophin is tightly associated with the sarcolemma of mammalian skeletal muscle fibers.

Zubrzycka-Gaarn EE, Hutter OF, Karpati G, Klamut HJ, Bulman DE, Hodges RS, Worton RG, Ray PN.

Exp Cell Res. 1991 Jan;192(1):278-88.

PMID:
1984418
34.

Molecular genetic approaches to the study of individual risk in alcoholism.

Worton RG.

Alcohol Alcohol Suppl. 1991;1:19-25. Review.

PMID:
1845536
35.

Immunogold labelling of dystrophin in human muscle, using an antibody to the last 17 amino acids of the C-terminus.

Cullen MJ, Walsh J, Nicholson LV, Harris JB, Zubrzycka-Gaarn EE, Ray PN, Worton RG.

Neuromuscul Disord. 1991;1(2):113-9.

PMID:
1822781
36.

Multipoint linkage analysis and heterogeneity testing in 20 X-linked retinitis pigmentosa families.

Musarella MA, Anson-Cartwright L, Leal SM, Gilbert LD, Worton RG, Fishman GA, Ott J.

Genomics. 1990 Oct;8(2):286-96.

37.
38.

Dystrophin is localized to the plasma membrane of human skeletal muscle fibers by electron-microscopic cytochemical study.

Carpenter S, Karpati G, Zubrzycka-Gaarn E, Bulman DE, Ray PN, Worton RG.

Muscle Nerve. 1990 May;13(5):376-80.

PMID:
2189068
39.
40.

Age-related conversion of dystrophin-negative to -positive fiber segments of skeletal but not cardiac muscle fibers in heterozygote mdx mice.

Karpati G, Zubrzycka-Gaarn EE, Carpenter S, Bulman DE, Ray PN, Worton RG.

J Neuropathol Exp Neurol. 1990 Mar;49(2):96-105.

PMID:
2407807
41.

Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.

MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Worton RG.

Nature. 1990 Feb 8;343(6258):559-61.

PMID:
1967823
42.

Molecular and functional analysis of the muscle-specific promoter region of the Duchenne muscular dystrophy gene.

Klamut HJ, Gangopadhyay SB, Worton RG, Ray PN.

Mol Cell Biol. 1990 Jan;10(1):193-205.

43.

Genetic and biochemical determinations in the pre-transplant workup and in the post-transplant assessment period.

Worton RG, Bulman DE, Zubrzycka-Gaarn EE, Ray PN.

Adv Exp Med Biol. 1990;280:219-25; discussion 225-6. No abstract available.

PMID:
2248141
44.

The DMD gene promoter: a potential role in gene therapy.

Ray PN, Klamut HJ, Worton RG.

Adv Exp Med Biol. 1990;280:107-11; discussion 111-2. Review.

PMID:
2248131
45.

Assignment of the gene for complete X-linked congenital stationary night blindness (CSNB1) to Xp11.3.

Musarella MA, Weleber RG, Murphey WH, Young RS, Anson-Cartwright L, Mets M, Kraft SP, Polemeno R, Litt M, Worton RG.

Genomics. 1989 Nov;5(4):727-37.

PMID:
2574143
46.

Gene inactivation as a mechanism for the expression of recessive phenotypes.

Grant SG, Campbell CE, Duff C, Toth SL, Worton RG.

Am J Hum Genet. 1989 Oct;45(4):619-34.

47.

Myogenic regulation of dystrophin gene expression.

Klamut HJ, Zubrzycka-Gaarn EE, Bulman DE, Malhotra SB, Bodrug SE, Worton RG, Ray PN.

Br Med Bull. 1989 Jul;45(3):681-702. Review.

PMID:
2688823
48.

Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation.

Karpati G, Pouliot Y, Zubrzycka-Gaarn E, Carpenter S, Ray PN, Worton RG, Holland P.

Am J Pathol. 1989 Jul;135(1):27-32.

49.

Evidence for mutation by unequal sister chromatid exchange in the Duchenne muscular dystrophy gene.

Hu XY, Burghes AH, Bulman DE, Ray PN, Worton RG.

Am J Hum Genet. 1989 Jun;44(6):855-63.

50.

Linkage analysis of a large Latin-American family with X-linked retinitis pigmentosa and metallic sheen in the heterozygote carrier.

Musarella MA, Anson-Cartwright L, Burghes A, Worton RG, Lesko JG, Nussbaum RL.

Genomics. 1989 May;4(4):601-5.

PMID:
2568332

Supplemental Content

Loading ...
Support Center